



BlueCross BlueShield of New Mexico

Medicare Advantage Prior Authorization Change Log Effective 10/1/2026

This list includes Current Procedural Terminology (CPT®) and/or Healthcare Common Procedure Coding System codes related to services/categories for which prior authorization may be required. This list is not exhaustive. The presence of codes on this list does not necessarily indicate coverage under the member benefits contract. Always check eligibility and benefits first, effective since before rendering services. Member contracts differ in their benefits. Consult the member benefit booklet, or contact a customer service representative to determine coverage for a specific medical service or supply.

Utilization Management Process

*This file is a searchable PDF.
Use <CTRL F> to find your selected criteria.*

Procedure Code	Code Description	Change	Change Effective Date
90999	Unlisted dialysis procedure, inpatient or outpatient	Add	10/1/2026
0029U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)	Remove	10/1/2026
0631U	Oncology (solid tumor), DNA, sequence analysis of 15 genes including BRCA1 and BRCA2 for identification of clonal hematopoiesis, blood, reported as tumor derived or non-tumor derived	Add	10/1/2026
0634U	Oncology (breast cancer), cell free DNA (cfDNA), evaluation of 11 ESR1 variants (E380Q, S463P, L536R, Y537C, Y537N, Y537S, D538G, V422del, L536H, L536P, Y537D) using droplet digital PCR (ddPCR), plasma, reported as positive or negative	Add	10/1/2026
0635U	Autoimmune (atopic dermatitis), mRNA, next generation sequencing (NGS), gene expression profiling of 487 genes, noninvasive skin surface scraping, algorithm reported as likelihood of response to therapy	Add	10/1/2026

0640U	Oncology (leptomeningeal metastases), tumor cell selection, identification, detection and enumeration based on differential CD318(CDCP1), SUSD2, CD340(erbB2/HER2), HGFR/cMET, FOLR1, EGFR, N cadherin, MUC1, EpCAM, and TROP2 antibody biomarkers, cerebrospinal fluid, reported as detection and quantification of tumor cells	Add	10/1/2026
0641U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), using formalin-fixed paraffin-embedded (FFPE) tissue and blood samples, initial (baseline) assessment	Add	10/1/2026
0642U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), whole blood, comparison to previously performed analyses, reported as trend in circulating tumor DNA (ctDNA) level	Add	10/1/2026
0643U	Oncology (genitourinary cancer), cell-free circulating tumor DNA (ctDNA), 200 genes, next-generation sequencing (NGS), interrogation for single nucleotide variants (SNVs), insertions/deletions, gene rearrangements, copy number alterations, and tumor mutation burden, using urine, identify and report mutations with clinical actionability	Add	10/1/2026
0644U	Oncology (leukemia), minimal residual disease (MRD) detection for rearrangements, blood or bone marrow, personalized assay design and baseline quantification	Add	10/1/2026
0645U	Oncology (leukemia), minimal residual disease (MRD) detection for rearrangements, based on digital PCR, blood or bone marrow, reported as not detected or detected with estimated abundance	Add	10/1/2026
0646U	Oncology (molecular residual disease), whole genome sequence analysis, cell-free DNA, whole blood, and formalin-fixed paraffin embedded (FFPE) tumor tissue DNA, baseline assessment	Add	10/1/2026

0647U	Oncology (molecular residual disease), whole genome sequence analysis, cell-free DNA (cfDNA), whole blood, assessment utilizing patient specific tumor information, reported as negative or percent circulating tumor DNA (ctDNA)	Add	10/1/2026
0648U	Oncology (solid tumor), targeted genomic sequencing analysis, to detect deletions, insertions, and substitutions in 42 genes, copy number amplifications in 10 genes, and fusions and splice variants in 18 driver genes from DNA and RNA extracted from formalin fixed paraffin-embedded (FFPE) tissue	Add	10/1/2026
0649U	Neurology (Alzheimer disease), DNA, targeted next generation sequencing (NGS) of AD-1 and AD-2 target regions, whole blood, prognostic algorithmic analysis, reported as categorization of cognitive status	Add	10/1/2026
0650U	Drug metabolism (adverse drug reactions and drug response), genotyping of 9 genes (ie, CYP2D6, CYP2C19, G6PD, SLCO1B1, HLA-B*58:01, NAT2, CYP2C9, VKORC1, ABCG2), reported as metabolizer status and transporter function	Add	10/1/2026
0651U	Oncology (hereditary cancer), genomic DNA, 55 hereditary cancer pre-dispositioned genes, next-generation sequencing (NGS) and digital multiplex ligation-dependent probe amplification for variants, small indels	Add	10/1/2026
0652U	Drug metabolism (adverse drug reactions), DNA analysis of 13 genes by targeted genotyping, using saliva or buccal swab, reported as diplotype and metabolizer status	Add	10/1/2026
0653U	Nephrology (inherited kidney disorders), DNA, analysis of approximately 700 genes associated with inherited kidney diseases by exome sequencing, using whole blood, saliva, or nail clipping, reported as an interpretive clinical report classifying pathogenic and likely pathogenic variants	Add	10/1/2026

0657U	Rare diseases (constitutional/heritable disorders), rapid whole genome sequence analysis of comparator nuclear and mitochondrial DNA by next generation sequencing (NGS), using blood or buccal sample, relevant variants reported with proband results (Use 0657U in conjunction with 0658U)	Add	10/1/2026
0658U	Rare diseases (constitutional/heritable disorders), rapid whole genome sequence analysis of nuclear and mitochondrial DNA by next-generation sequencing (NGS) for single nucleotide variants (SNVs), insertions/deletions, copy number variants, uniparental disomy, and repeat expansions, using blood or buccal sample, identification and categorization of genetic variants (Use 0658U in conjunction with 0657U)	Add	10/1/2026
0659U	Rare diseases (constitutional/heritable disorders), ultrarapid whole genome sequence analysis of nuclear and mitochondrial DNA by next-generation sequencing (NGS) for single nucleotide variants (SNVs), insertions/deletions, copy number variants, uniparental disomy, and repeat expansions, using blood or buccal sample, identification and categorization of genetic variants	Add	10/1/2026
1049T	Autologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 50 sq cm, or each additional 0.5% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)	Add	10/1/2026
1050T	Insertion, subcutaneous heart failure decompensation monitor, containing sensors that measure, at a minimum, heart rate, impedance, respiration rate, physical activity, heart sounds	Add	10/1/2026
1051T	Removal of subcutaneous heart failure decompensation monitor	Add	10/1/2026

1052T	Interrogation device evaluation(s), (in person or remote) up to 30 days, insertable subcutaneous heart failure decompensation monitor, analysis of physiologic parameters, including, at a minimum, heart rate, impedance, respiration rate, physical activity, heart sounds, with generation of a report, review and interpretation by a physician or other qualified health care professional	Add	10/1/2026
1053T	Programming device evaluation (in person or remote) of subcutaneous heart failure decompensation monitor, with analysis of physiologic parameters, including, at a minimum, heart rate, impedance, respiration rate, physical activity, heart sounds, with generation of a report and review and interpretation by a physician or other qualified health care professional	Add	10/1/2026
A4238	monthly supply allowance for an adjunctive, non-implanted Continuous Glucose Monitor (CGM).	Add	10/1/2026
A4239	monthly supply allowance for a non-adjunctive, non-implanted continuous glucose monitor (CGM)	Add	10/1/2026
C9309	Injection, onasemnogene abeparvovec-brve, per treatment	Remove	10/1/2026
E0784	External ambulatory infusion pump, insulin	Add	10/1/2026
E2100	Blood glucose monitor with integrated voice synthesizer.	Add	10/1/2026
E2101	blood glucose monitor equipped with an integrated lancing and blood sampling mechanism	Add	10/1/2026
E2102	adjunctive, non-implanted continuous glucose monitor (CGM) or receiver	Add	10/1/2026
E2103	non-adjunctive, non-implanted continuous glucose monitor (CGM) or receiver	Add	10/1/2026
J1289	Injection, narsoplimab-wuug, 1 mg	Add	10/1/2026
J1562	Injection, immune globulin (Vivaglobin), 100 mg	Remove	10/1/2026
J2789	Riboflavin 5'-phosphate, ophthalmic solution (epioxahd/epioxa), up to 2 ml	Add	10/1/2026

J3386	Injection, etuvetidigene autotemcel, per treatment	Add	10/1/2026
J3405	Injection, onasemnogene abeparvovec-brve, per treatment	Add	10/1/2026
J7176	Injection, human fibrinogen - chmt (fesilty), 1 mg	Add	10/1/2026
J9037	Injection, belantamab mafodotin-blmf, 0.5 mg	Remove	10/1/2026
J9053	Injection, belantamab mafodotin-blmf, 0.1 mg	Add	10/1/2026
J9062	Injection, amivantamab 5 mg and hyaluronidase-lpuj	Add	10/1/2026
J9232	Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg	Add	10/1/2026
J9352	Injection, trabectedin, 0.1 mg	Remove	10/1/2026
J9362	Injection, trabectedin, 0.01 mg	Add	10/1/2026
Q2017	Injection, teniposide, 50 mg	Remove	10/1/2026
Q2058	Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Add	10/1/2026
Q4353	Xceed tl matrix, per square centimeter (add-on, list separately in addition to primary procedure)	Add	10/1/2026

CPT copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the AMA.

Checking eligibility and/or benefit information and/or obtaining prior authorization is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member contract or member guide, including, but not limited to, exclusions and limitations applicable on the date services were rendered. If you have any questions, call the number on the member's ID card. Regardless of any prior authorization or benefit determination, the final decision regarding any treatment or service is between the patient and their health care provider

EviCore healthcare is an independent specialty medical benefits management company that provides utilization management services for Blue Cross and Blue Shield of New Mexico. Prime Therapeutics LLC is a pharmacy benefit management company. BCBSNM contracts with Prime to provide pharmacy benefit management and other related services. BCBSNM, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime.

BCBSNM makes no endorsement, representations or warranties third party vendors and the products and services they offer.